Bard1 Life Sciences Limited (BD1:ASX)


right-arrow Created with Sketch. -0.02 (-0.78%)
MCAP $204.1M
Last trade 16.10pm 07/05/2021 20mins delayed

Latest Announcements

30/04/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
29/04/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
16/04/2021BD1Bard1 Life Sciences Limited
13/04/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
19/03/2021BD1Bard1 Life Sciences Limited
16/03/2021 Price SensitivePSBD1Bard1 Life Sciences Limited
15/03/2021BD1Bard1 Life Sciences Limited
15/03/2021BD1Bard1 Life Sciences Limited

Company Overview

BARD1 Life Sciences Limited is an Australia-based medical diagnostics company. The Company is focused on the development and commercialization of diagnostic solutions for health care professionals and patients. The Company’s technologies include BARD1, hTERT, SIEN-NET and SubB2M. The hTERT is an immunocytochemistry (ICC) assay that detects human telomerase reverse transcriptase (hTERT). The BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins and autoantibodies. The SIEN-NET is a biomarker capture platform that captures and purifies target molecules from patient samples. The SubB2M is a pan-cancer probe that is specific for cancer cells and complements other technologies and biomarkers to detect cancer using a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and positron emission tomography (PET) imaging.

BD1 in the news

Search Previous Announcements